Patents by Inventor Gregory M. Acland

Gregory M. Acland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170014529
    Abstract: A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.
    Type: Application
    Filed: July 27, 2016
    Publication date: January 19, 2017
    Inventors: Gregory M. Acland, Gustavo D. Aguirre, Jean Bennett, William H. Hauswirth, Samuel G. Jacobson, Albert M. Maguire
  • Publication number: 20160263246
    Abstract: A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.
    Type: Application
    Filed: May 4, 2016
    Publication date: September 15, 2016
    Inventors: Gregory M. Acland, Gustavo D. Aguirre, Jean Bennett, William W. Hauswirth, Samuel G. Jacobson, Albert M. Maguire
  • Patent number: 9433688
    Abstract: A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: September 6, 2016
    Assignees: The Trustees of the University of Pennsylvania, University of Florida Research Foundation, Incorporated, Cornell Research Foundation, Inc.
    Inventors: Gregory M. Acland, Gustavo D. Aguirre, Jean Bennett, William W. Hauswirth, Samuel G. Jacobson, Albert M. Maguire
  • Publication number: 20140377224
    Abstract: A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.
    Type: Application
    Filed: June 20, 2014
    Publication date: December 25, 2014
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED, CORNELL RESEARCH FOUNDATION, INC.
    Inventors: Gregory M. Acland, Gustavo D. Aguirre, Jean Bennett, William W. Hauswirth, Samuel G. Jacobson, Albert M. Maguire
  • Publication number: 20120225930
    Abstract: A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.
    Type: Application
    Filed: February 28, 2012
    Publication date: September 6, 2012
    Inventors: Gregory M. Acland, Gustavo D. Aguirre, Jean Bennett, William W. Hauswirth, Samuel G. Jacobson, Albert M. Maguire
  • Patent number: 8206911
    Abstract: Tools and methods are provided for determining whether or not a dog is genetically normal, is a carrier of, or is affected with or predisposed to progressive rod-cone degeneration. The method is based on the detection of a transversion from G to A at position corresponding to nucleotide position 1298 of SEQ ID NO: 1.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: June 26, 2012
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Gustavo Aguirre, Gregory M. Acland, Barbara Zangerl, Orly Goldstein, Susan Pearce-Kelling, Jeanette S. Felix, Duska J. Sidjanin
  • Patent number: 8147823
    Abstract: A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: April 3, 2012
    Assignees: The Trustees of the University of Pennsylvania, University of Florida Research Foundation, Incorporated, Cornell Research Foundation Inc.
    Inventors: Gregory M. Acland, Gustavo D. Aguirre, Jean Bennett, William W. Hauswirth, Samuel G. Jacobson, Albert M. Maguire
  • Patent number: 8119343
    Abstract: Provided are methods for identifying dogs as likely to be genetically normal, carriers of, or affected with Oculo-skeletal dysplasia (OSD) by determining the presence or absence of a drd2 COL9A2 mutation and/or a drd1 COL9A3 mutation. Also provided is a method for selective breeding of dogs and kits useful for carrying out the methods of the invention.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: February 21, 2012
    Assignee: Cornell University
    Inventors: Gregory M. Acland, Orly Goldstein, Anna V. Kukekova, Jennifer Lynn Johnson
  • Publication number: 20100323349
    Abstract: Tools and methods are provided for determining whether or not a dog is genetically normal, is a carrier of, or is affected with or predisposed to progressive rod-cone degeneration. The method is based on the detection of a transversion from G to A at position corresponding to nucleotide position 1298 of SEQ ID NO: 1.
    Type: Application
    Filed: March 1, 2010
    Publication date: December 23, 2010
    Inventors: Gustavo Aguirre, Gregory M. Acland, Barbara Zangerl, Orly Goldstein, Susan Pearce-Kelling, Jeanette S. Felix, Duska J. Sidjanin
  • Publication number: 20100272688
    Abstract: A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.
    Type: Application
    Filed: July 8, 2010
    Publication date: October 28, 2010
    Applicants: The Trustees of the University of Pennsylvania, University of Florida Research Foundation, Incorporated, Cornell Research Fountaintion, Inc.
    Inventors: Gregory M. Acland, Gustavo D. Aguirre, Jean Bennett, William W. Hauswirth, Samuel G. Jacobson, Albert M. Maguire
  • Patent number: 7811761
    Abstract: Provided is a method for identifying dogs as likely to be genetically normal, carriers of, or affected with progressive rod-cone degeneration comprising analyzing nucleic acids from a dog and determining the presence or absence of one or more prcd polymorphisms in the nucleic acids. Representative prcd polymorphisms characteristic of a prcd haplotype are also provided.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: October 12, 2010
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Gregory M. Acland, Gustavo D. Aguirre, Orly Goldstein, Barbara Zangerl, Susan Pearce-Kelling, Duska J. Sidjanin, Jeanette S. Felix
  • Patent number: 7723507
    Abstract: The invention relates to a method for identifying dogs which are genetically normal, heterozygous for, or homozygous for the mutation primarily responsible for Collie eye anomaly (CEA). The method comprises the steps of obtaining a biological sample from a dog and testing DNA in the biological sample for the presence or absence of a 7.8 kilobase deletion within chromosome 37 in which the CEA mutation is located. No deletion is indicative of a normal dog. A deletion on one allele of chromosome 37 is indicative of a dog that is heterozygous for the CEA mutation. A deletion in both alleles of chromosome 37 are indicative of a dog that is homozygous for the CEA mutation. Also provided is a kit for identifying a dog as normal, heterozygous for, or homozygous for the CEA mutation.
    Type: Grant
    Filed: September 22, 2008
    Date of Patent: May 25, 2010
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Gregory M. Acland, Anna V. Kukekova, Gustavo D. Aguirre, Elaine Ostrander, Dayna Akey, Orly Goldstein
  • Patent number: 7671187
    Abstract: Tools and methods are provided for determining whether or not a dog is genetically normal, is a carrier of, or is affected with or predisposed to progressive rod-cone degeneration. The method is based on the detection of a transversion from G to A at position corresponding to nucleotide position 1298 of SEQ ID NO: 1.
    Type: Grant
    Filed: November 13, 2007
    Date of Patent: March 2, 2010
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Gustavo Aguirre, Gregory M. Acland, Barbara Zangerl, Orly Goldstein, Susan Pearce-Kelling, Jeanette S. Felix, Duska J. Sidjanin
  • Publication number: 20090176225
    Abstract: The invention relates to a method for identifying dogs which are genetically normal, heterozygous for, or homozygous for the mutation primarily responsible for Collie eye anomaly (CEA). The method comprises the steps of obtaining a biological sample from a dog and testing DNA in the biological sample for the presence or absence of a 7.8 kilobase deletion within chromosome 37 in which the CEA mutation is located. No deletion is indicative of a normal dog. A deletion on one allele of chromosome 37 is indicative of a dog that is heterozygous for the CEA mutation. A deletion in both alleles of chromosome 37 are indicative of a dog that is homozygous for the CEA mutation. Also provided is a kit for identifying a dog as normal, heterozygous for, or homozygous for the CEA mutation.
    Type: Application
    Filed: September 22, 2008
    Publication date: July 9, 2009
    Inventors: Gregory M. Acland, Anna V. Kukekova, Gustavo D. Aguirre, Elaine Ostrander, Dayna Akey, Orly Goldstein
  • Publication number: 20090111976
    Abstract: Tools and methods are provided for determining whether or not a dog is genetically normal, is a carrier of, or is affected with or predisposed to progressive rod-cone degeneration. The method is based on the detection of a transversion from G to A at position corresponding to nucleotide position 1298 of SEQ ID NO: 1.
    Type: Application
    Filed: November 13, 2007
    Publication date: April 30, 2009
    Inventors: Gustavo Aguirre, Gregory M. Acland, Barbara Zangerl, Orly Goldstein, Susan Pearce-Kelling, Jeanette S. Felix, Duska J. Sidjanin
  • Publication number: 20090074723
    Abstract: A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.
    Type: Application
    Filed: October 18, 2008
    Publication date: March 19, 2009
    Applicants: The Trustees of the University of Pennsylvania, The University of Florida Research Foundation, Inc., Cornell Research Foundation, Inc.
    Inventors: Gregory M. Acland, Gustavo D. Aguirre, Jean Bennett, William W. Hauswirth, Samuel G. Jacobson, Albert M. Maguire
  • Publication number: 20090061448
    Abstract: Provided are methods for identifying dogs as likely to be genetically normal, carriers of, or affected with Oculo-skeletal dysplasia (OSD) by determining the presence or absence of a drd2 COL9A2 mutation and/or a drd1 COL9A3 mutation. Also provided is a method for selective breeding of dogs and kits useful for carrying out the methods of the invention.
    Type: Application
    Filed: August 27, 2008
    Publication date: March 5, 2009
    Applicant: Cornell Research Foundation, Inc.
    Inventors: Gregory M. Acland, Orly Goldstein, Anna V. Kukekova, Jennifer Lynn Johnson
  • Patent number: 7462455
    Abstract: The invention relates to a method for identifying dogs which are genetically normal, heterozygous for, or homozygous for the mutation primarily responsible for Collie eye anomaly (CEA). The method comprises the steps of obtaining a biological sample from a dog and testing DNA in the biological sample for the presence or absence of a 7.8 kilobase deletion within chromosome 37 in which the CEA mutation is located. No deletion is indicative of a normal dog. A deletion on one allele of chromosome 37 is indicative of a dog that is heterozygous for the CEA mutation. A deletion in both alleles of chromosome 37 are indicative of a dog that is homozygous for the CEA mutation. Also provided is a kit for identifying a dog as normal, heterozygous for, or homozygous for the CEA mutation.
    Type: Grant
    Filed: October 20, 2005
    Date of Patent: December 9, 2008
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Gregory M. Acland, Anna V. Kukekova, Gustavo D. Aguirre, Elaine Ostrander, Dayna Akey, Orly Goldstein
  • Patent number: 7312037
    Abstract: Tools and methods are provided for determining whether or not a dog is genetically normal, is a carrier of, or is affected with or predisposed to progressive rod-cone degeneration. The method is based on the detection of a transversion from G to A at position corresponding to nucleotide position 1298 of SEQ ID NO: 1.
    Type: Grant
    Filed: June 21, 2005
    Date of Patent: December 25, 2007
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Gustavo Aguirre, Gregory M. Acland, Barbara Zangerl, Orly Goldstein, Susan Pearce-Kelling, Jeanette S. Felix, Duska J. Sidjanin
  • Publication number: 20040022766
    Abstract: A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.
    Type: Application
    Filed: November 20, 2002
    Publication date: February 5, 2004
    Inventors: Gregory M. Acland, Gustayo D. Aguirre, Jean Bennett, William W. Hauswirth, Samuel G. Jacobson, Albert M. Maguire